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012.11.00Abstract Aim of the work: To evaluate the clinical signiﬁcance of serum levels of interleukin-6
(IL-6) and 174 G/C promoter polymorphism in Rheumatoid arthritis (RA) patients.
Patients and methods: We studied 37 RA patients and 10 age and gender matched healthy con-
trols. Demographic, clinical and serological data were prospectively evaluated. Disease activity
score (DAS28) and Health Assessment Questionnaire (HAQ) were assessed. Serum IL-6 level
was measured and promoter (174G/C) genotyped.
Results: Serum IL-6 levels were signiﬁcantly higher in RA patients compared to control
(p= 0.04), especially those with CC promoter polymorphism. Twenty-four patients had GG
IL-6 (174 G/C) gene promoter polymorphism, 11 were GC and 2 CC. Nine controls were GG
and 1 GC. In patients with more advanced polymorphism (174 CC) there was a signiﬁcantly
increased functional impairment (HAQ score) (p= 0.029) and platelet count (p= 0.049). In those
with GG genotype, there was a signiﬁcant correlation between IL-6 and Morning stiffness duration
(r= 0.44,p= 0.03), while those with GC genotype had a signiﬁcant negative correlation of the IL-6
level with the parameters of disease activity and the DAS28 (r= 0.69,p= 0.019). None of the
studied parameters would predict the IL-6 promoter polymorphism.
Conclusion: Serum IL-6 levels and 174 G/C promoter polymorphism were higher in RA
patients than in healthy controls. The inverse relation of IL-6 with the DAS28 in those with an238956697; Mobile +20
om (G.S. Azkalany).
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108 W. Gaber et al.increased IL-6 promoter polymorphism may conﬁrm its increased involvement in the pathogenesis
of RA and in the increased disease activity which may point to the need for considering of anti-IL-6
agents in their management plan.
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Rheumatoid arthritis (RA) is a chronic, systemic, inﬂamma-
tory, multi-factorial disease sustained by environmental and ge-
netic factors. These seem to be necessary but not sufﬁcient in
the disease development, nonetheless they can be responsible
of different clinical pictures and response to therapy, and rep-
resent potential therapeutic targets. Several genes have been
indicated so far in the pathogenesis of RA [1]. Substantial evi-
dence has implicated interleukin-6 (IL-6) in the pathogenesis of
RA [2]. The role of the variability of IL-6 production in the
pathogenesis and severity of RA is genetically determined [3]
and its174 promoter polymorphism is associated with disease
susceptibility and activity and forms a genetic risk factor [4].
Interleukin-6 (IL-6) is a cytokine that can facilitate autoim-
mune phenomena, amplify acute inﬂammation and promote
the evolution into a chronic inﬂammatory state. In addition,
IL-6 has a pivotal role in synovitis, bone erosions and in the
systemic features of inﬂammation [5]. The transition from
acute to chronic inﬂammation is characterized by a change
in cellular inﬁltrate from predominantly polymorphonuclear
neutrophils to mononuclear cells, and IL-6 is a key regulator
of this process [2]. Its serum concentrations are signiﬁcantly
elevated in RA patients and they decreased with medical treat-
ment proposing a potential role for IL-6 family cytokines in
the pathogenesis of RA [6]. Being a key cytokine for B cell sur-
vival and proliferation, IL-6 (174) promoter polymorphism
was identiﬁed as a genetic biomarker of response to biologics
in RA [7]. The IL-6 system plays a sensitive role in local
inﬂammatory reactions by amplifying leukocyte recruitment
and has the capacity to protect against lipopolysaccharide
[8]. A role for functional polymorphism and genetically deter-
mined lower soluble IL-6 receptor (IL-6R) levels has been sug-
gested as a risk factor for RA [9].
Gene polymorphisms such as those located at Tumor
Necrosis Factor (TNF), IL-1 and IL-6 seem to be responsible
for more aggressive disease phenotype. The efforts in the post-
genomic era can bring to an estimation of the real likelihood of
the genetic effect [1]. The 174 C allele confers a higher mor-
tality and plasma level of IL-6 in patients with abdominal aor-
tic aneurysm [10] and a signiﬁcantly higher relative risk of
coronary heart disease in healthy subjects [11]. In a study on
Egyptian patients with pemphigus, the IL-6 174 CC genotype
has been reported to represent a marker of increased suscepti-
bility while the GG genotype can be considered a low-risk
genotype [12]. Rheumatoid patients homozygous for the IL6
174 GG genotype had more severe endothelial dysfunction
than those carrying the GC or CC genotypes [13]. Given the
pleiotropic function of IL-6 it can be anticipated that other
inﬂammatory diseases and bone metabolic conditions might
beneﬁt from selective IL-6 signaling inhibition [5]. Despite
the important physiological activities of IL-6, dysregulated
overproduction is pathologically involved in variousimmune-mediated inﬂammatory diseases other than RA, such
as systemic lupus erythematosus, adult-onset Still disease,
Takayasu arthritis, polyarteritis nodosa, systemic sclerosis,
reactive arthritis, dermatomyositis and polymyositis [14].
By virtue of its multiple effects, IL-6 is involved in the
various phases of RA development, including the acute phase,
immuno-inﬂammatory phase, and destructive phase. IL-6 has
an impact on the many pathogenic factors identiﬁed in RA
and, consequently, holds promise for targeted treatments and
monoclonal antibody (tocilizumab) to transmembrane and sol-
uble IL-6Ra has been found effective. Tocilizumab is now indi-
cated for the treatment of adults with RA who have failed at
least one synthetic disease-modifying antirheumatic drug or
TNFa antagonist [15]. The discovery of new genes associated
with the disease can be relevant in ﬁnding potential biomark-
ers, potentially useful in disease diagnosis and treatment [1].
The clinical efﬁcacy of IL-6 inhibition also underlines the
important contribution of this cytokine in RA [16].
The aim of the present study was to evaluate the clinical sig-
niﬁcance of serum levels of Interleukin-6 (IL-6) and 174 G/C
promoter polymorphism in Rheumatoid arthritis (RA)
patients and ﬁnd any association to the clinical and laboratory
features and disease activity.
2. Patients and methods
2.1. Study design
Thirty-seven patients (35 females and 2 males) with deﬁnite
RA diagnosed according to the 2010 ACR/EULAR RA clas-
siﬁcation criteria [17] were consecutively recruited from the
Rheumatology outpatient clinic and department of Cairo Uni-
versity Hospitals. Full history taking and thorough clinical
examination were performed for all the patients. Laboratory
investigations in the form of complete blood count (CBC),
erythrocyte sedimentation rate (ESR), rheumatoid factor
(RF) and anti-cyclic citrullinated peptide (anti-CCP) and plain
X-ray of the affected joints were assessed. All patients were
regularly receiving methotrexate with or without corticoste-
roids and chloroquine. Disease activity score (DAS-28) was
calculated [18]. The Health Assessment Questionnaire-II
(HAQ-II) was used [19]. Radiological grading of the hands
and feet of the studied RA patients was assessed and percent-
age damage was calculated according to the modiﬁed Larsen
score [20]. Informed consents were taken from the patients
and the study was approved by the local ethics committee.
2.2. Methods
2.2.1. Determination of serum IL-6 level
Serum IL-6 was assayed using Human IL-6 ELISA kit (quan-
titative sandwich enzyme immunoassay technique), provided
by Ray Biotech, Inc. (www.raybiotech.com).
Table 1 Demographic, clinical, laboratory and radiological
features of RA patients.
Feature RA patients No. (37)
mean ± SD
Age (years) 44.49 ± 13.46
Disease duration (years) 8.91 ± 7.15
Morning stiﬀness (min.) 23.51 ± 38.94
No. of swollen joints 1.73 ± 3.16
No. of tender joints 5.89 ± 8.19
VAS (mm) 30.14 ± 32.61
ESR (mm/1st hr) 54.57 ± 24.4
Hemoglobin (g/dl) 11.23 ± 1.59
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polymorphism
Promoter region polymorphism of IL-6 gene (174 G/C) was
determined by polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) technique. DNA isolation
and IL-6 genotyping: genomic DNA was isolated from white
blood cells (WBCs) of peripheral blood using Biospin Whole
Blood Genomic DNA Extraction Kit (Bioﬂux Corporation,
Arrow Plaza, Tokyo, Japan).Enzymatic ampliﬁcation was per-
formed by PCR using Master Taq polymerase enzyme and Hy-
brid thermal cycler (Promega Corporation, 2800 Woods
Hollow Road Madison, W 153711–5399 USA). Ampliﬁcation
of the promoter region (174G/C) of the IL-6 gene was done
as proposed by Pola et al. [21] using 2 primers (were purchased
from Operon Biotechnologies (GmbH/Biocampus, Germany).
Forward Primer: 50- GCC TCA ATG ACG ACC TAA GC-30,
and Reverse Primer: 50- TCA TGGGAA AAT CCC ACA TT-
30. The PCR reaction mixture (25 ll) contained 12.5 ll 2· PCR
Master Mix {10 · PCR buffer, 4 mM MgCl2, 0.5 Taq DNA
polymerase/ll, 0.4 mM dNTPs (dATP, dCTP, dGTP, dTTP)},
1 ll of each primer (25 pmol), 3 ll of genomic DNA and 7.5 ll
sterilized nuclease-free water. The reaction was carried out
with the following cycles: 95 C for 5 min; 35 cycles of 30 s
denaturation at 95 C, 30 s annealing at 61 C and 30 s
extension at 72 C and a 10-min ﬁnal extension at 72 C after
completion of the cycles. Then ampliﬁed products were
digested with 5 units of Fast Digest NLa III restriction enzyme
at 37 C for 10 min (supplied by Fermentas, LT-02241 Vilnius,
Lithuania). The digested products were then detected in 3.5%
agarose gel containing ethidium bromide by performing E/P
on the gel electrophoresis apparatus and visualized by UV
transillumination (Promega, USA). A single band at 163 bp
identiﬁed GG homozygous individuals, two bands at 111
and 52 bp identiﬁed CC homozygous individuals, and three
bands at 163, 111 and 52 bp indicated a GC heterozygote.
Statistical analysis: The data were collected, tabulated and
analyzed by SPSS package version 15 (SPSS corporation,
USA). Data were summarized as mean ± SD. Mann–Whitney
tests were used for comparative analysis of 2 quantitative data.
Non-parametric analysis of variance (Kruskall–Wallis) was
used for comparison of more than two groups; Spearman’s
correlation analysis was used for detection of the relation
between 2 variables. Logistic regression analysis was applied
to detect the predictors for the elevated IL-6 level and pro-
moter polymorphism. Results were considered signiﬁcant at
p< 0.05.Platelets (x103/ml) 293.49 ± 86.35
IL-6 (pg/ml) 58.45 ± 147.09
Modiﬁed Larsen score 38.55 ± 16.94
DAS28 4.37 ± 1.73
HAQ-II 0.71 ± 0.73
Medications:
Methotrexate (30/37) (mg/week) 14.59 ± 8.71 [17.5;0–25]
Prednisolone (15/37) (mg/day) 2.84 ± 3.69 [0;0–10]
Leﬂunomide (8/37) (mg/day) 4.05 ± 7.98 [0;0–20]
Chloroquine (16/37) (mg/day) 108.11 ± 125.56 [0;0–250]
VAS: visual analogue scale, ESR: erythrocyte sedimentation rate,
IL-6: Interleukin 6, DAS28: Disease activities score for 28 joints,
HAQ: health assessment questionnaire. Values between square
brackets represent the median and range.3. Results
There were 37 RA patients (35 females and 2 males) and 10 age
and sex matched healthy controls with a mean age of
44.3 ± 2.91 years (9 females and 1 male). The mean IL-6 level
for controls (7.71 ± 8.59 pg/ml) was signiﬁcantly lower than
the level in patients (p= 0.044). The demographic, clinical
and laboratory features of the RA patients are presented in
Table 1. Medications used are also presented in the table
and all the patients were irregularly receiving declophenac so-
dium (50–100 mg) while only one was receiving full dose of sul-
phasalazine (2000 mg/day). Three of the patients were diabetic
and hypertensive with two of them having hepatitis C virus(HCV) which was also present in another two patients. The
rheumatoid factor was positive in 35 patients (94.6%) and
anti-CCP was positive in 78.38%. None of the patients gave
family history for any rheumatic disease.
There were 24 patients (64.86%) with GG IL-6 (174 G/C)
gene promoter polymorphism, 11 (29.73%) with GC and 2
(5.41%) with CC, while 9 (90%) of the control showed GG
genotype with one individual with GC. The IL-6 was signiﬁ-
cantly higher in patients with CC (546 ± 343.65 pg/ml) com-
pared to those with GG (12.54 ± 14.82 pg/ml) and GC
(69.97 ± 113.23 pg/ml), (p< 0.0001) (Fig. 1).
Furthermore, there was a signiﬁcant difference in the plate-
let count which was 268.54 ± 73.36 · 103/mm3 for those with
GG genotype, 335.36 ± 99.81 · 103/mm3 for GC and being
the highest (362.5 ± 36.06 · 103/mm3) in those with CC
(p= 0.049). Similarly, the more advanced the promoter poly-
morphism, the more the functional impairment of the patients
as assessed by the HAQ-II score which was 0.6 ± 0.65 for
those with GG genotype, 0.62 ± 0.19 with GC and 2 ± 1.41
for those with CC (p= 0.029). The modiﬁed Larsen score
tended to be higher in those with CC genotype, however the
difference was not signiﬁcant. The RA patients with positive
anti-CCP antibodies had a signiﬁcantly higher modiﬁed Larsen
score (41.32 ± 16.53) compared to those with negative test
(21.25 ± 3.77) (p= 0.001); however the difference in DAS28
was insigniﬁcant (p= 0.5). There were no other signiﬁcant dif-
ferences in the characteristic features of the patients according
to the promoter genes.
Those with associated HCV had a tendency to an elevated
IL-6 level (275.35 ± 370.2 pg/ml) compared to those without
(32.16 ± 69.98 pg/ml) (p= 0.28), higher DAS28 (5.63 ±
2.15 vs 4.22 ± 1.65, p = 0.28) and impaired functional status
Figure 1 Box plot of the serum IL-6 level in the RA patients and
control according to the IL-6 (174 G/C) promoter polymor-
phism type.
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two of these patients had CC promoter polymorphism.
In the studied RA patients the IL-6 level signiﬁcantly neg-
atively correlated with the age at disease onset (r= 0.34,
p= 0.037) while there was a tendency for this association be-
tween gene polymorphism and age at disease onset (r= 0.32,
p= 0.057). The age at disease onset was older in those with
GG genotype (38.29 ± 13.72 years), 32.59 ± 11.11 years in
those with GC genotype and was younger in 2 patients with
CC genotype (19.5 ± 3.54 years). In those with GG genotype,Figure 2 Correlation of the serum IL-6 level and the DAS28 in
RA patients with GC 174 promoter polymorphism.there was a signiﬁcant correlation between IL-6 level and dura-
tion of the morning stiffness (MS) (r= 0.44, p= 0.033).
While in those with GC genotype there was a signiﬁcant neg-
ative correlation of the IL-6 level with the number of swollen
joints (r= 0.68, p= 0.22), number of tender joints, VAS
for pain (r= 0.7, p= 0.017), positive anti-CCP (r= 0.34,
p= 0.039) and the DAS28 (r= 0.69, p= 0.019) (Fig. 2).
Furthermore, the positivity of anti-CCP correlated with the
modiﬁed Larsen score (r = 0.52, p= 0.013). No signiﬁcant
correlation was present between IL-6 level and disease dura-
tion, other clinical features (MS, number of swollen joints,
number of tender joints, visual analogue score VAS), other
laboratory investigations (erythrocyte sedimentation rate
ESR, hemoglobin content Hb and platelet count), steroid dose
and disease activity (DAS28). None of the studied clinical and
laboratory parameters would predict the IL-6 promoter
polymorphism.
4. Discussion
In the current study, the mean serum IL-6 level was signiﬁ-
cantly higher in RA patients than in control. In agreement,
higher levels of IL-6 were present in serum, synovial
tissue and synovial ﬂuid from patients with RA compared to
those with non-inﬂammatory arthritis [2,6]. Furthermore,
there was a signiﬁcant difference in the genotype and allele fre-
quency at 174 of IL-6 between RA patients and healthy sub-
jects [22]. On the other hand, another study found that the
distribution of IL-6 genotypes in RA patients did not differ
from that in control subjects [4]. Chronic joint inﬂammation
in RA leads to the production of IL-6 and its receptor (IL-
6R), which is expressed on effector cells that cause and prolong
inﬂammation. Interleukin-6 is over-expressed in synovial tissue
in RA patients, with raised concentrations in serum and syno-
vial ﬂuid [23].
In the present study on Egyptian RA patients, there were
64.86% with GG IL-6 (174 G/C) gene promoter polymor-
phism, 29.73% with GC and 5.41% with CC, while 90% of
the control showed GG genotype with one individual present-
ing with GC. In disagreement to the present study results, no
signiﬁcant differences in the IL-6 174 allele or genotype
frequencies between RA patients and controls were found.
However, a role of IL-6 174 gene polymorphism in the devel-
opment of subclinical atherosclerosis in patients with RA was
supported [13]. Moreover, another study found that the pro-
moter polymorphism frequency of the IL-6 C allele was lower
in RA patients than in controls [3]. There is a possible associa-
tion between IL-6 promoter polymorphisms, at position 174,
and outcome of RA. No difference was observed in the distri-
bution of IL-6 promoter genotype or allele frequencies between
RA patients and controls which appears to rule out an impor-
tant role of IL-6 promoter polymorphisms in the susceptibility
to RA in a Spanish population [8]. In a recent meta-analysis
study, it was found that IL-6 174 G/C polymorphism may
confer susceptibility to RA in Europeans [24].
In the present study, the IL-6 was signiﬁcantly higher in
those with CC compared to those with GG and GC genotypes.
Contrarily, allele 174 C is associated with a reduced IL-6
promoter strength of expression and IL-6 serum levels are low-
er in subjects with the CC genotype compared with GC or GG
subjects [8]. Others stated that no deﬁnite association between
gene polymorphisms and IL-6 serum levels was noticed [25].
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level of IL-6 was higher compared to those without HCV. The
difference was insigniﬁcant, however the number of patients
included is small to withdraw a reliable conclusion. Two of
these HCV associated patients had promoter polymorphism
(IL6 174 CC). The IL-6 level was found elevated in HCV
patients and after clearing HCV infection, the level signiﬁ-
cantly decreased [26,27]. The high serum levels of IL-6
described in the course of RA have been linked to its enhanced
activity. Furthermore, the high level in patients with HCV
related arthritis indicates an increased synthesis and hyperac-
tivity of this cytokine. The substantial similarity of the behav-
ior of IL-6 in the RA and HCV-related arthritis patients
suggests common mechanisms, in which the function of I
L-6 is central [28]. It has been reported that IL-6 promoter
polymorphisms inﬂuence the development of chronic HCV
infection [29].
In the present study, the higher the promoter polymor-
phism, the more the functional impairment of the patients as
assessed by the HAQ score and more the increased platelet
count. In those with GG genotype, there was a signiﬁcant cor-
relation between IL-6 level and duration of the MS and in
those with the GC genotype IL-6 showed a signiﬁcant inverse
correlation with the parameters of disease activity and the
DAS28. The pro-inﬂammatory role of the IL6 system in estab-
lished RA has been highlighted by the use of anti-sIL-6R anti-
bodies [3]. However, a protective effect of IL6 on the risk of
developing RA is suggested [3] which may further explain
the inverse correlation in the present study. The consumption
and involvement of IL-6 with its receptor in the active RA pa-
tients may further explain the inverse relation. On the other
hand, in a previous study, IL-6 levels in RA patients correlated
positively with disease activity [30]. In another study, in pa-
tients with a GG genotype, the active form of RA was more
frequently diagnosed compared with CC and GC patients.
Moreover, in carriers of two G alleles the parameters of
DAS28, ESR, and number of swollen and tender joints were
signiﬁcantly increased [4]. Others found no signiﬁcant relation-
ship between IL-6 cytokine levels and DAS28 [6]. In RA
patients, a similar apparent decline in DAS28 occurred with
either abatacept or tocilizumab therapy except that the de-
creased disease activity was more rapid among tocilizumab-
treated patients, directly caused by IL-6 inhibition [31].
Thrombopoietin acts as an acute phase protein but is not un-
iquely responsible for thrombocytosis of inﬂammatory disor-
ders, while IL-6 positively correlated with the platelet count
which makes it recognized as a credible candidate and as a
cooperating factor [32]. Impairment of physical function and
health-related quality of life, as well as fatigue (a major debil-
itating factor in RA), were all improved more with anti-IL6
tocilizumab than with placebo, reﬂecting substantial func-
tional beneﬁts for the patients [23].
In the present study, there was no correlation of the serum
IL-6 level with the MS, however, in those with GG genotype
there was a signiﬁcant correlation. In RA patients with MS,
there may be insufﬁcient endogenous cortisol released during
the night to counter elevated levels of Il-6 [33]. Some RA pa-
tients in remission still experience prolonged MS and thus it re-
mains an important marker of active disease that should
continue to be monitored [34]. Major improvement in MS
was observed in RA patients treated by IL-6-receptor antago-nist tocilizumab. Meanwhile, the disease activity did not differ
between RF-positive and negative patients [35].
In the present study, there were no other signiﬁcant differ-
ences in the characteristic features of the RA patients accord-
ing to the promoter genes. Similarly, with regard to clinical
and laboratory parameters, no differences were found accord-
ing to the sex, duration, extraarticular manifestations, DAS28,
baseline HAQ, RF and anti-CCP statuses according to the dif-
ferent IL-6 174 genotypes [7,8].
In the studied RA patients, the IL-6 level signiﬁcantly neg-
atively correlated with the age at disease onset while there was
a tendency for this association between gene polymorphism
and age at disease onset. In harmony were the results that
found an observed signiﬁcant difference in the mean age at dis-
ease onset between IL-6 genotypes and considered that this
points to the possible contribution to the pathogenesis by
inﬂuencing the age at disease onset [8]. Interestingly, a signiﬁ-
cant difference in the mean age at disease onset was lower in
patients at 174 CC than those at 174 GG and the age for
heterozygous 174 CG was intermediate between means for
homozygotes [8].
In the present study there was no signiﬁcant difference in
the Modiﬁed Larsen score among the RA patients according
to the promoter genes however, the score tended to be higher
in those with CC genotype. Contrarily, the IL6 174G allele
polymorphism is associated with more severe radiologic dam-
age in RA [3]. Interleukin-6 gene (174G/C) has been associ-
ated with bone erosive damage in RA patients especially those
with CC genotype [36]. Of particular relevance to RA, IL-6 in-
duces osteoclast differentiation, contributing to joint destruc-
tion, bone resorption and osteoporosis [23]. Targeting IL-6
seems an attractive therapeutic option in this disease, since it
has a pivotal role in mediating inﬂammation, auto-antibody
production, joint destruction and also systemic manifestations
of RA. It is considered the most abundant cytokine in joints
and serum of RA patients and its levels are correlated with
the disease activity [23].
IL-6 (174) promoter polymorphism may be a genetic risk
factor determining the effectiveness of RA treatment with
methotrexate and glucocorticoids as the incidence of remission
after therapy was signiﬁcantly lower in patients with GG geno-
type compared with GC and CC [37]. Targeting IL-6R with a
humanized anti IL-6R monoclonal antibody (tocilizumab)
effectively controls local and systemic inﬂammatory manifesta-
tions and blocks cartilage and bone destruction [5]. Blocking
IL-6 can be a therapeutic option for patients with autoimmune
diseases in which overproduction of IL-6 plays a pathological
role and future clinical studies investigating the safety and efﬁ-
cacy will elucidate the clinical beneﬁts [14]. Lack of response to
rituximab was more prevalent in RA patients with the IL-6
174 CC genotypes than in the GC/GG patients suggesting
that IL-6 promoter genotyping may be useful to a better treat-
ment plan with RTX in RA [7,25].
In conclusion, serum IL-6 levels and 174 G/C promoter
polymorphism were higher in RA patients than in healthy con-
trols. None of the studied parameters would predict the IL-6
level and promoter polymorphism. In those with IL-6 174
GC promoter polymorphism, the increased disease activity
was inversely related to the serum IL-6 level. The positive cor-
relation of IL-6 with the duration of morning stiffness is of
clinical signiﬁcance. To conﬁrm our results we propose that
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